vs

Side-by-side financial comparison of Centuri Holdings, Inc. (CTRI) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.

EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $858.6M, roughly 1.0× Centuri Holdings, Inc.). Centuri Holdings, Inc. runs the higher net margin — 3.5% vs -9.8%, a 13.3% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 19.7%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $66.3M). Over the past eight quarters, Centuri Holdings, Inc.'s revenue compounded faster (27.5% CAGR vs 17.4%).

Centuri, formerly known as Allied Leisure, was an American arcade game manufacturer. They were based in Hialeah, Florida, and were one of the top six suppliers of coin-operated arcade video game machinery in the United States during the early 1980s. Centuri in its modern inception was formed when former Taito America president Ed Miller and his partner Bill Olliges took over Allied Leisure, Inc. They renamed it "Centuri" in 1980. The company's vice president was Joel Hochberg from about 1976 ...

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

CTRI vs EXAS — Head-to-Head

Bigger by revenue
EXAS
EXAS
1.0× larger
EXAS
$878.4M
$858.6M
CTRI
Growing faster (revenue YoY)
EXAS
EXAS
+3.4% gap
EXAS
23.1%
19.7%
CTRI
Higher net margin
CTRI
CTRI
13.3% more per $
CTRI
3.5%
-9.8%
EXAS
More free cash flow
EXAS
EXAS
$54.1M more FCF
EXAS
$120.4M
$66.3M
CTRI
Faster 2-yr revenue CAGR
CTRI
CTRI
Annualised
CTRI
27.5%
17.4%
EXAS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTRI
CTRI
EXAS
EXAS
Revenue
$858.6M
$878.4M
Net Profit
$30.4M
$-86.0M
Gross Margin
9.4%
70.1%
Operating Margin
4.3%
-9.4%
Net Margin
3.5%
-9.8%
Revenue YoY
19.7%
23.1%
Net Profit YoY
194.1%
90.1%
EPS (diluted)
$0.34
$-0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRI
CTRI
EXAS
EXAS
Q4 25
$858.6M
$878.4M
Q3 25
$850.0M
$850.7M
Q2 25
$724.1M
$811.1M
Q1 25
$550.1M
$706.8M
Q4 24
$717.1M
$713.4M
Q3 24
$720.1M
$708.7M
Q2 24
$672.1M
$699.3M
Q1 24
$528.0M
$637.5M
Net Profit
CTRI
CTRI
EXAS
EXAS
Q4 25
$30.4M
$-86.0M
Q3 25
$2.1M
$-19.6M
Q2 25
$8.1M
$-1.2M
Q1 25
$-17.9M
$-101.2M
Q4 24
$10.3M
$-864.6M
Q3 24
$-3.7M
$-38.2M
Q2 24
$11.7M
$-15.8M
Q1 24
$-25.1M
$-110.2M
Gross Margin
CTRI
CTRI
EXAS
EXAS
Q4 25
9.4%
70.1%
Q3 25
9.2%
68.6%
Q2 25
9.4%
69.3%
Q1 25
3.7%
70.8%
Q4 24
9.9%
69.0%
Q3 24
10.5%
69.4%
Q2 24
9.0%
69.8%
Q1 24
2.5%
70.0%
Operating Margin
CTRI
CTRI
EXAS
EXAS
Q4 25
4.3%
-9.4%
Q3 25
4.3%
-3.0%
Q2 25
4.4%
-0.3%
Q1 25
-2.3%
-13.6%
Q4 24
4.7%
-122.8%
Q3 24
5.8%
-5.6%
Q2 24
4.9%
-3.8%
Q1 24
-4.2%
-16.7%
Net Margin
CTRI
CTRI
EXAS
EXAS
Q4 25
3.5%
-9.8%
Q3 25
0.2%
-2.3%
Q2 25
1.1%
-0.1%
Q1 25
-3.3%
-14.3%
Q4 24
1.4%
-121.2%
Q3 24
-0.5%
-5.4%
Q2 24
1.7%
-2.3%
Q1 24
-4.7%
-17.3%
EPS (diluted)
CTRI
CTRI
EXAS
EXAS
Q4 25
$0.34
$-0.45
Q3 25
$0.02
$-0.10
Q2 25
$0.09
$-0.01
Q1 25
$-0.20
$-0.54
Q4 24
$0.17
$-4.69
Q3 24
$-0.04
$-0.21
Q2 24
$0.14
$-0.09
Q1 24
$-0.35
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRI
CTRI
EXAS
EXAS
Cash + ST InvestmentsLiquidity on hand
$126.6M
$964.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$873.0M
$2.4B
Total Assets
$2.4B
$5.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRI
CTRI
EXAS
EXAS
Q4 25
$126.6M
$964.7M
Q3 25
$16.1M
$1.0B
Q2 25
$28.3M
$858.4M
Q1 25
$15.3M
$786.2M
Q4 24
$49.0M
$1.0B
Q3 24
$52.5M
$1.0B
Q2 24
$30.9M
$946.8M
Q1 24
$18.4M
$652.1M
Stockholders' Equity
CTRI
CTRI
EXAS
EXAS
Q4 25
$873.0M
$2.4B
Q3 25
$585.2M
$2.5B
Q2 25
$567.1M
$2.5B
Q1 25
$536.5M
$2.4B
Q4 24
$555.6M
$2.4B
Q3 24
$527.3M
$3.2B
Q2 24
$530.4M
$3.2B
Q1 24
$197.8M
$3.1B
Total Assets
CTRI
CTRI
EXAS
EXAS
Q4 25
$2.4B
$5.9B
Q3 25
$2.2B
$5.9B
Q2 25
$2.1B
$5.8B
Q1 25
$2.0B
$5.7B
Q4 24
$2.1B
$5.9B
Q3 24
$2.1B
$6.7B
Q2 24
$2.2B
$6.7B
Q1 24
$2.1B
$6.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRI
CTRI
EXAS
EXAS
Operating Cash FlowLast quarter
$83.9M
$151.7M
Free Cash FlowOCF − Capex
$66.3M
$120.4M
FCF MarginFCF / Revenue
7.7%
13.7%
Capex IntensityCapex / Revenue
2.0%
3.6%
Cash ConversionOCF / Net Profit
2.76×
TTM Free Cash FlowTrailing 4 quarters
$-8.2M
$356.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRI
CTRI
EXAS
EXAS
Q4 25
$83.9M
$151.7M
Q3 25
$5.2M
$219.9M
Q2 25
$-27.7M
$89.0M
Q1 25
$16.7M
$30.8M
Q4 24
$61.0M
$47.1M
Q3 24
$180.2M
$138.7M
Q2 24
$-56.6M
$107.1M
Q1 24
$-26.5M
$-82.3M
Free Cash Flow
CTRI
CTRI
EXAS
EXAS
Q4 25
$66.3M
$120.4M
Q3 25
$-18.4M
$190.0M
Q2 25
$-48.5M
$46.7M
Q1 25
$-7.7M
$-365.0K
Q4 24
$27.8M
$10.7M
Q3 24
$160.7M
$112.6M
Q2 24
$-76.9M
$71.2M
Q1 24
$-52.7M
$-120.0M
FCF Margin
CTRI
CTRI
EXAS
EXAS
Q4 25
7.7%
13.7%
Q3 25
-2.2%
22.3%
Q2 25
-6.7%
5.8%
Q1 25
-1.4%
-0.1%
Q4 24
3.9%
1.5%
Q3 24
22.3%
15.9%
Q2 24
-11.4%
10.2%
Q1 24
-10.0%
-18.8%
Capex Intensity
CTRI
CTRI
EXAS
EXAS
Q4 25
2.0%
3.6%
Q3 25
2.8%
3.5%
Q2 25
2.9%
5.2%
Q1 25
4.4%
4.4%
Q4 24
4.6%
5.1%
Q3 24
2.7%
3.7%
Q2 24
3.0%
5.1%
Q1 24
5.0%
5.9%
Cash Conversion
CTRI
CTRI
EXAS
EXAS
Q4 25
2.76×
Q3 25
2.48×
Q2 25
-3.43×
Q1 25
Q4 24
5.90×
Q3 24
Q2 24
-4.84×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTRI
CTRI

Master Services Agreement$660.7M77%
Non Union Electric Segment$163.4M19%
Related Party$25.6M3%

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

Related Comparisons